| Year |
Citation |
Score |
| 2023 |
Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T. Proposal for a Biologic Staging System of Parkinson's Disease. Journal of Parkinson's Disease. PMID 37066922 DOI: 10.3233/JPD-225111 |
0.402 |
|
| 2023 |
Merchant KM, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman KNH, Tengstrandt E, Hsieh F, Alcalay RN, Coffey C, Chahine L, Foroud T, Singleton A, Weintraub D, Hutten S, ... Sherer T, et al. LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts. Npj Parkinson's Disease. 9: 30. PMID 36854767 DOI: 10.1038/s41531-023-00468-2 |
0.351 |
|
| 2022 |
Frasier M, Fiske BK, Sherer TB. Precision medicine for Parkinson's disease: The subtyping challenge. Frontiers in Aging Neuroscience. 14: 1064057. PMID 36533178 DOI: 10.3389/fnagi.2022.1064057 |
0.422 |
|
| 2022 |
Schiess N, Cataldi R, Okun MS, Fothergill-Misbah N, Dorsey ER, Bloem BR, Barretto M, Bhidayasiri R, Brown R, Chishimba L, Chowdhary N, Coslov M, Cubo E, Di Rocco A, Dolhun R, ... ... Sherer T, et al. Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority. Jama Neurology. PMID 35816299 DOI: 10.1001/jamaneurol.2022.1783 |
0.419 |
|
| 2020 |
Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107 |
0.46 |
|
| 2020 |
Dorsey E, Sherer T, Okun M, Bloem B. The Rise of Parkinson's Disease American Scientist. 108: 176. DOI: 10.1511/2020.108.3.176 |
0.396 |
|
| 2019 |
Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, ... ... Sherer T, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337. PMID 30745444 DOI: 10.1212/Wnl.0000000000006926 |
0.602 |
|
| 2019 |
Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, ... ... Sherer T, et al. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism & Related Disorders. PMID 30738748 DOI: 10.1016/j.parkreldis.2018.12.025 |
0.407 |
|
| 2018 |
Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. Journal of Parkinson's Disease. 8: S3-S8. PMID 30584159 DOI: 10.3233/Jpd-181474 |
0.305 |
|
| 2018 |
Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, ... ... Sherer T, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology. 5: 1460-1477. PMID 30564614 DOI: 10.1002/Acn3.644 |
0.468 |
|
| 2018 |
Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, ... ... Sherer T, et al. Finding useful biomarkers for Parkinson's disease. Science Translational Medicine. 10. PMID 30111645 DOI: 10.1126/Scitranslmed.Aam6003 |
0.438 |
|
| 2018 |
Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, ... ... Sherer T, et al. Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29572948 DOI: 10.1002/Mds.27361 |
0.386 |
|
| 2016 |
Sherer TB, Frasier MA, Langston JW, Fiske BK. Parkinson's disease is ready for precision medicine. Personalized Medicine. 13: 405-407. PMID 29767601 DOI: 10.2217/pme-2016-0052 |
0.389 |
|
| 2015 |
Dorsey ER, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdhury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, et al. Feasibility of Virtual Research Visits in Fox Trial Finder. Journal of Parkinson's Disease. 5: 505-15. PMID 26406130 DOI: 10.3233/JPD-150549 |
0.326 |
|
| 2015 |
Rocker C, Cappelletti L, Marshall C, Meunier CC, Brooks DW, Sherer T, Chowdhury S. Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder. Journal of Parkinson's Disease. 5: 55-66. PMID 25624422 DOI: 10.3233/JPD-140522 |
0.356 |
|
| 2014 |
Jankovic J, Sherer T. The future of research in Parkinson disease Jama Neurology. 71: 1351-1352. PMID 25178587 DOI: 10.1001/jamaneurol.2014.1717 |
0.311 |
|
| 2014 |
Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, ... ... Sherer TB, et al. Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. Neurobiology of Disease. 70: 190-203. PMID 24969022 DOI: 10.1016/j.nbd.2014.06.009 |
0.391 |
|
| 2014 |
Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 772-9. PMID 24610195 DOI: 10.1002/mds.25859 |
0.385 |
|
| 2013 |
Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA. A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Disease Models & Mechanisms. 6: 1316-24. PMID 24046356 DOI: 10.1242/dmm.011940 |
0.387 |
|
| 2012 |
Sherer TB, Chowdhury S, Peabody K, Brooks DW. Overcoming obstacles in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1606-11. PMID 23115047 DOI: 10.1002/mds.25260 |
0.422 |
|
| 2011 |
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Sherer T, Frasier M, Meunier C, et al. The Parkinson Progression Marker Initiative (PPMI) Progress in Neurobiology. 95: 629-635. PMID 21930184 DOI: 10.1016/J.Pneurobio.2011.09.005 |
0.416 |
|
| 2011 |
Sherer TB. Biomarkers for Parkinson's disease. Science Translational Medicine. 3: 79ps14. PMID 21508309 DOI: 10.1126/scitranslmed.3002488 |
0.422 |
|
| 2010 |
Frasier M, Chowdhury S, Eberling J, Sherer T. Biomarkers in Parkinsons disease: A funders perspective Biomarkers in Medicine. 4: 723-729. PMID 20945984 DOI: 10.2217/bmm.10.89 |
0.315 |
|
| 2009 |
Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H. Funding of Parkinson research from industry and US federal and foundation sources. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 731-7. PMID 19133662 DOI: 10.1002/Mds.22446 |
0.393 |
|
| 2007 |
Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. Journal of Neurochemistry. 100: 1469-79. PMID 17241123 DOI: 10.1111/J.1471-4159.2006.04333.X |
0.782 |
|
| 2007 |
Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicological Sciences : An Official Journal of the Society of Toxicology. 95: 196-204. PMID 17038483 DOI: 10.1093/Toxsci/Kfl133 |
0.708 |
|
| 2006 |
Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 136-41. PMID 16470786 DOI: 10.1002/mds.20861 |
0.417 |
|
| 2006 |
Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease. 22: 404-20. PMID 16439141 DOI: 10.1016/J.Nbd.2005.12.003 |
0.791 |
|
| 2005 |
Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. The Journal of Biological Chemistry. 280: 42026-35. PMID 16243845 DOI: 10.1074/Jbc.M508628200 |
0.601 |
|
| 2005 |
Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Sciences : An Official Journal of the Society of Toxicology. 88: 193-201. PMID 16141438 DOI: 10.1093/Toxsci/Kfi304 |
0.666 |
|
| 2005 |
Sherer TB, Greenamyre JT. Oxidative damage in Parkinson's disease. Antioxidants & Redox Signaling. 7: 627-9. PMID 15890006 DOI: 10.1089/ars.2005.7.627 |
0.622 |
|
| 2005 |
Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Research. Molecular Brain Research. 134: 109-18. PMID 15790535 DOI: 10.1016/J.Molbrainres.2004.11.007 |
0.739 |
|
| 2005 |
Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Experimental Neurology. 191: S17-27. PMID 15629758 DOI: 10.1016/J.Expneurol.2004.08.021 |
0.733 |
|
| 2005 |
Sherer TB, Betarbet R, Greenamyre JT. Rotenone rat and other neurotoxin models of parkinson disease Movement Disorders. 161-172. DOI: 10.1016/B978-012088382-0/50013-X |
0.599 |
|
| 2004 |
Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, Casida JE. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chemical Research in Toxicology. 17: 1540-8. PMID 15540952 DOI: 10.1021/Tx049867R |
0.676 |
|
| 2004 |
Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Experimental Neurology. 187: 76-85. PMID 15081590 DOI: 10.1016/J.Expneurol.2003.12.012 |
0.618 |
|
| 2003 |
Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10756-64. PMID 14645467 DOI: 10.1523/Jneurosci.23-34-10756.2003 |
0.761 |
|
| 2003 |
Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism & Related Disorders. 9: S59-64. PMID 12915069 DOI: 10.1016/S1353-8020(03)00023-3 |
0.714 |
|
| 2003 |
Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience Letters. 341: 87-90. PMID 12686372 DOI: 10.1016/S0304-3940(03)00172-1 |
0.698 |
|
| 2003 |
Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental Neurology. 179: 9-16. PMID 12504863 DOI: 10.1006/Exnr.2002.8072 |
0.714 |
|
| 2002 |
Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT. Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathology (Zurich, Switzerland). 12: 499-510. PMID 12408237 DOI: 10.1111/J.1750-3639.2002.Tb00468.X |
0.748 |
|
| 2002 |
Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 7006-15. PMID 12177198 |
0.69 |
|
| 2002 |
Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson's disease. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 8: 192-7. PMID 12061498 DOI: 10.1177/1073858402008003004 |
0.751 |
|
| 2002 |
Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 24: 308-18. PMID 11948617 DOI: 10.1002/Bies.10067 |
0.72 |
|
| 2002 |
Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage The Journal of Neuroscience. 22: 7006-7015. DOI: 10.1523/Jneurosci.22-16-07006.2002 |
0.696 |
|
| 2001 |
Sherer TB, Betarbet R, Greenamyre JT. Pesticides and Parkinson's disease. Thescientificworldjournal. 1: 207-8. PMID 12805673 DOI: 10.1100/Tsw.2001.35 |
0.713 |
|
| 2001 |
Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. Iubmb Life. 52: 135-41. PMID 11798025 DOI: 10.1080/15216540152845939 |
0.723 |
|
| 2001 |
Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease. Current Opinion in Investigational Drugs (London, England : 2000). 2: 657-62. PMID 11569943 |
0.719 |
|
| 2001 |
Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP, Tuttle JB. Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Research. 891: 94-105. PMID 11164812 DOI: 10.1016/S0006-8993(00)03203-0 |
0.398 |
|
| 2001 |
Greenamyre JT, Betarbet R, Sherer T, Panov A. Response: Parkinson's disease, pesticides and mitochondrial dysfunction Trends in Neurosciences. 24: 247. DOI: 10.1016/S0166-2236(00)01788-4 |
0.747 |
|
| 2000 |
Sherer T, Greenamyre JT. A therapeutic target and biomarker in Friedreich's ataxia. Neurology. 55: 1600-1. PMID 11113210 |
0.452 |
|
| 2000 |
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience. 3: 1301-6. PMID 11100151 DOI: 10.1038/81834 |
0.788 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Kurowska Z, Kordower JH, Stoessl AJ, Burke R, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, Medicetty S. Is Axonal Degeneration a Key Early Event in Parkinson's Disease? Journal of Parkinson's Disease. PMID 27497486 DOI: 10.3233/Jpd-160881 |
0.299 |
|
| 2023 |
Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, ... ... Sherer T, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. The Lancet. Neurology. 22: 407-417. PMID 37059509 DOI: 10.1016/S1474-4422(23)00109-6 |
0.292 |
|
| 2008 |
Fiske BK, Frasier MA, Sherer TB. Special focus section: gene therapy for Parkinson's disease. Experimental Neurology. 209: 28-9. PMID 17980867 DOI: 10.1016/j.expneurol.2007.09.006 |
0.275 |
|
| 2024 |
Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, ... ... Sherer T, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. The Lancet. Neurology. 23: 178-190. PMID 38267190 DOI: 10.1016/S1474-4422(23)00405-2 |
0.262 |
|
| 2013 |
Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. Plos One. 8: e80705. PMID 24244710 DOI: 10.1371/journal.pone.0080705 |
0.205 |
|
| 1999 |
Tuttle JB, Sherer TB, Durieux ME, Steers WD. Anesthetics Inhibit Nerve Growth Factor Output By Bladder Smooth Muscle The Journal of Urology. 39. DOI: 10.1097/00005392-199904010-00157 |
0.189 |
|
| 2020 |
Baptista MAS, Merchant K, Barrett T, Bhargava S, Bryce DK, Ellis JM, Estrada AA, Fell MJ, Fiske BK, Fuji RN, Galatsis P, Henry AG, Hill S, Hirst W, Houle C, ... ... Sherer TB, et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Science Translational Medicine. 12. PMID 32321864 DOI: 10.1126/Scitranslmed.Aav0820 |
0.188 |
|
| 2014 |
McDevitt VL, Mendez-Hinds J, Winwood D, Nijhawan V, Sherer T, Ritter JF, Sanberg PR. MORE THAN MONEY: THE EXPONENTIAL IMPACT OF ACADEMIC TECHNOLOGY TRANSFER. Technology and Innovation. 16: 75-84. PMID 25061505 DOI: 10.3727/194982414X13971392823479 |
0.183 |
|
| 2015 |
Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P, Lee DW, Lewin-Koh SC, Lin T, Liu X, Liu S, ... ... Sherer T, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine. 7: 273ra15. PMID 25653221 DOI: 10.1126/Scitranslmed.Aaa3634 |
0.161 |
|
| 2014 |
Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, et al. Overcoming obstacles to repurposing for neurodegenerative disease. Annals of Clinical and Translational Neurology. 1: 512-8. PMID 25356422 DOI: 10.1002/Acn3.76 |
0.159 |
|
| 2022 |
Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, et al. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort. Npj Parkinson's Disease. 8: 140. PMID 36273008 DOI: 10.1038/s41531-022-00404-w |
0.157 |
|
| 2020 |
Kane PB, Benjamin DM, Barker RA, Lang AE, Sherer T, Kimmelman J. Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33002259 DOI: 10.1002/mds.28319 |
0.156 |
|
| 1999 |
Steers WD, Clemow DB, Persson K, Sherer TB, Andersson KE, Tuttle JB. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Experimental Physiology. 84: 137-47. PMID 10081714 DOI: 10.1111/J.1469-445X.1999.Tb00079.X |
0.152 |
|
| 2016 |
Wyse RK, Brundin P, Sherer TB. Nilotinib - Differentiating the Hope from the Hype. Journal of Parkinson's Disease. PMID 27434298 DOI: 10.3233/JPD-160904 |
0.151 |
|
| 2000 |
Sherer TB, Trimmer PA, Parks JK, Tuttle JB. Mitochondrial DNA-depleted neuroblastoma (Rho degrees) cells exhibit altered calcium signaling. Biochimica Et Biophysica Acta. 1496: 341-55. PMID 10771102 DOI: 10.1016/S0167-4889(00)00027-6 |
0.15 |
|
| 2014 |
Choi DW, Armitage R, Brady LS, Coetzee T, Fisher W, Hyman S, Pande A, Paul S, Potter W, Roin B, Sherer T. Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs. Neuron. 84: 554-63. PMID 25442934 DOI: 10.1016/J.Neuron.2014.10.027 |
0.139 |
|
| 2012 |
Ereshefsky L, Frasier M, Yen M, Jhee S, Marek K, Taylor P, Sherman M, Caspell C, Coffey C, Schlossmacher M, Sherer T. P1-021: Diurnal and intersubject variability of cerebrospinal fluid biomarkers, Aβ-40/42, alpha-synuclein and DJ-1 in healthy volunteers Alzheimer's & Dementia. 8: P114-P115. DOI: 10.1016/J.Jalz.2012.05.296 |
0.134 |
|
| 2020 |
Kane PB, Benjamin DM, Barker RA, Lang AE, Sherer T, Kimmelman J. Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. Journal of Parkinson's Disease. PMID 32333550 DOI: 10.3233/Jpd-201933 |
0.129 |
|
| 1999 |
Sherer TB, Neff PS, Parks JK, Tuttle JB. Mitochondrial impact on nerve growth factor production in vascular smooth muscle-derived cells. Biochimica Et Biophysica Acta. 1473: 305-20. PMID 10594368 DOI: 10.1016/S0304-4165(99)00194-4 |
0.083 |
|
| 1999 |
Steers WD, Clemow DB, Persson K, Sherer T, Andersson KE, Tuttl JB. Observations from the spontaneously hypertensive rat: Insight into NGF regulation and noradrenergic hyper-innervation in the lower urinary tract Advances in Experimental Medicine and Biology. 462: 283-292. PMID 10599432 |
0.067 |
|
| 1997 |
Sherer TB, Spitsbergen JM, Steers WD, Tuttle JB. Thrombin regulates nerve growth factor secretion from vascular, but not bladder smooth muscle cells. Cell and Tissue Research. 289: 155-61. PMID 9182610 DOI: 10.1007/s004410050861 |
0.066 |
|
| 2023 |
Vukmirovic M, Benam KH, Rose JJ, Turner S, Magin CM, Lagares D, Cohen AH, Kaminski N, Hirota JA, Maher TM, Königshoff M, Mallampalli RK, Sheppard D, Tarran R, Gomer RH, ... ... Sherer T, et al. Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena: An Official American Thoracic Society Report. Annals of the American Thoracic Society. PMID 37903340 DOI: 10.1513/AnnalsATS.202310-872ST |
0.057 |
|
| 1998 |
Sherer TB, Neff PS, Hankins GR, Tuttle JB. Mechanisms of increased NGF production in vascular smooth muscle of the spontaneously hypertensive rat. Experimental Cell Research. 241: 186-93. PMID 9633527 DOI: 10.1006/excr.1998.4043 |
0.056 |
|
| 1998 |
Sherer TB, Neff PS, Tuttle JB. Increased nerve growth factor mRNA stability may underlie elevated nerve growth factor secretion from hypertensive vascular smooth muscle cells. Brain Research. Molecular Brain Research. 62: 167-74. PMID 9813306 DOI: 10.1016/S0169-328X(98)00247-2 |
0.05 |
|
| 2016 |
Akil H, Balice-Gordon R, Cardozo DL, Koroshetz W, Posey Norris SM, Sherer T, Sherman SM, Thiels E. Neuroscience Training for the 21st Century. Neuron. 90: 917-26. PMID 27253446 DOI: 10.1016/J.Neuron.2016.05.030 |
0.047 |
|
| 2021 |
Coetzee T, Ball MP, Boutin M, Bronson A, Dexter DT, English RA, Furlong P, Goodman AD, Grossman C, Hernandez AF, Hinners JE, Hudson L, Kennedy A, Marchisotto MJ, Myers E, ... ... Sherer T, et al. Data Sharing Goals for Nonprofit Funders of Clinical Trials. Journal of Participatory Medicine. 13: e23011. PMID 33779573 DOI: 10.2196/23011 |
0.043 |
|
| 2000 |
Sherer TB, Clemow DB, Tuttle JB. Calcium homeostasis and nerve growth factor secretion from vascular and bladder smooth muscle cells. Cell and Tissue Research. 299: 201-11. PMID 10741461 DOI: 10.1007/s004410050018 |
0.033 |
|
| 2013 |
Sherer TB. Money without collaboration won't bring cures. Nature Medicine. 19: 127. PMID 23389601 DOI: 10.1038/nm0213-127 |
0.017 |
|
| 2012 |
Frail DE, Degennaro L, Schimmer A, Kasper J, Winneker R, Sherer TB, Urkowitz A, Dave KD, Panetta J, Mccall J. Drug Repositioning Efforts by Nonprofit Foundations Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. 389-431. DOI: 10.1002/9781118274408.ch12 |
0.015 |
|
| 2021 |
Coetzee T, Ball MP, Boutin M, Bronson A, Dexter DT, English RA, Furlong P, Goodman AD, Grossman C, Hernandez AF, Hinners JE, Hudson L, Kennedy A, Marchisotto MJ, Matrisian L, ... ... Sherer T, et al. Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials. Journal of Participatory Medicine. 13: e31371. PMID 34255670 DOI: 10.2196/31371 |
0.01 |
|
| 2012 |
Meunier C, Jennings D, Hunter C, Sherer T. Fox Trial Finder: An Innovative Web-Based Trial Matching Tool To Facilitate Clinical Trial Recruitment (P02.241) Neurology. 78: P02.241-P02.241. DOI: 10.1212/wnl.78.1_meetingabstracts.p02.241 |
0.01 |
|
| 2004 |
Warren WL, Gabridge MG, Sherer T, Baile CA, Kennedy SJ. University start-up patent licensing tactics Genetic Engineering News. 24: 20+23. |
0.01 |
|
| Hide low-probability matches. |